Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU

Journal of Pharmacy Practice

Volumn 23, Issue 1, 2010, Pages 33-37

  Coyle, Elizabeth A ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antifungal; Candida; Critically ill; Fungal infections; Resistance; Susceptibility

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID DERIVATIVE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; CANDIDEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNGUS CULTURE; HUMAN; INJECTION SITE REACTION; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MORBIDITY; MORTALITY; NEPHROTOXICITY; REVIEW; TREATMENT RESPONSE;

EID: 77949403462     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009356552     Document Type: Review

References (28)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20: 133-163.
2. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Anitfungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735-1745.
3. Playford EG, Eggimann P, Calandra T. Antifungals in the ICU. Curr Opin Infect Dis. 2008;21:610-619.
4. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
5. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
6. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12:204-212.
7. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(suppl 2):S87-S91.
8. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
9. Hollenbach E. Invasive candidiasis in the ICU: evidence based and on the edge of evidence. Mycoses. 2008;51(suppl 2):25-45.
10. Wisplinghoff H, Bischoff T, Tallen SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
11. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. epidemiology and diagnosis. Intensive Care Med. 2009;35:55-62.
12. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150-156.
13. Shorr AF, Lasarus DR, Sherner JH, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med. 2007;35: 1077-1083.
14. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999: National Nosocomial Infections Surveillance System Hospitals. Clin Infect Dis. 2002;35:627-630.
15. Fleck R, Hof H. Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values. Mycoses. 2008;51(suppl 2):1-4.
16. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother. 2009;53:1185-1193.
17. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52: 4181-4183.
18. Baixench MT, Aoun N, Desno-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother. 2007;59:1076-1083.
19. Garnacho-Montero J, Diaz-Martin A, Cayuela-Dominguez A. Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy. Int J Antimicrob Agents. 2008;32(suppl 2):S137-S141.
20. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967-2972.
21. Morrell M, Fraser VJ, Kollef MH. Delaying empiric treatment of Candida bloodstream infections until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-3645.
22. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
23. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624-1633.
24. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI document M27-A3.
25. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435-447.
26. Posteraro B, Martucci R, La Sorda M, et al. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J Clin Microbiol. 2009;47: 1927-1930.
27. Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis. 2006;19:538-543.
28. Collins CD, Eschenauer GA, Salo SL, Newton DW. To test of not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J Clin Microbiol. 2007;45:1884-1888.